(WebFG News) - Regenerative medical devices company Tissue Regenix Group announced on Tuesday that, following the successful completion of the manufacturing technical transfer, it has begun sales of 'DermaPure' products processed at the CellRight Technologies facility in San Antonio, Texas.
Regenerative medical devices company Tissue Regenix Group announced the launch of a new operating division on Monday - 'TRX BioSurgery'.
Regenerative medical devices company Tissue Regenix Group announced the appointment of Steve Couldwell as its chief executive officer on Thursday, effective immediately.
AIM-listed regenerative medical devices company Tissue Regenix Group's saw operating losses widen at the interim stage even as its revenues nudged higher, although it did gain regulatory approval for its products in Europe and the US.
Regenerative medical device company Tissue Regenix released an update on two of its devices for a potential pilot study and product launch.
Tissue Regenix announced its first step towards the commercialisation of two of its products on Tuesday, through a joint venture agreement with a German tissue bank.
Regenerative medical devices group Tissue Regenix has received approval for DermaPure(R) reimbursement from two further administrators of the Medicare health insurance programme in the US.
Shares in Tissue Regenix jumped on Tuesday, after the producer of devices for regenerative medicine said it had taken a "critical step" towards securing approval for a new treatment.
Tissue Regenix has received a decision to grant a European patent covering the use of its technology, strengthening its plan to issue a global roll-out of dCELL.
Tissue Regenix surged on Thursday after the launch of its skincare device DermaPure in the US following the signing of an exclusive government supplier partnership with TASSMA for the distribution of the treatment.
British American Tabacco: Credit Suisse reduces target price from 3700p to 3550p and retains its outperform rating.
Numis Securities has kept its 'hold' rating and 2,250p target price for cruise operator Carnival ahead of its annual results next week, saying it may be too early for the firm to increase guidance.
Panmure Gordon has hiked its target price for AIM-listed medical devices company Tissue Regenix (TRX) by over a fifth after the signing of new sales distribution agreements in the US, highlighting the possibility that the firm could become a bid target in the future.
AIM-listed Tissue Regenix has agreed seven sales distribution agreements in the US to promote its DermaPure human skin replacement device into hospitals.
First half losses increased slightly at regenerative medicine specialist Tissue Regenix as it drove its products further towards commercialisation with several senior appointments made in the US.